Literature DB >> 34445984

Assessment of the correlation of commonly used laboratory tests with clinical activity, renal involvement and treatment of systemic small-vessel vasculitis with the presence of ANCA antibodies.

Magdalena Mosakowska1, Dorota Brodowska Kania2, Katarzyna Szamotulska3, Aleksandra Rymarz2, Stanisław Niemczyk2.   

Abstract

BACKGROUND: The aim of the study was to assess the correlation of commonly used laboratory tests with clinical activity, degree of kidney involvement and treatment of systemic small-vessel vasculitis with the presence of ANCA antibodies.
METHODS: The study included 28 patients with active AAV (BVAS ≥ 3). The following tests were performed: MPO-ANCA, PR3-ANCA, peripheral blood count, ESR, CRP, procalcitonin, creatinine, GFR, urea, albumin, fibrinogen, d-dimer, components of the C3 and C4 complement systems, urinalysis with sediment evaluation and diurnal proteinuria. The assessments were conducted twice: at study entry (A0) and after 6 months (A6) (BVAS = 0).
RESULTS: At the time of inclusion in the study, the mean creatinine concentration was 3.39 mg/dl (GFR 33.17 ml/min/1.73 m²), after achieving remission in 11 patients (39.3 %) GFR remained below 30 ml/min/1.73 m², 4 patients (14.3 %) continued renal replacement therapy, and 3 patients (10.7 %) with advanced renal failure died. Microscopic hematuria occurred in 80.9 % of the studied population, withdrew in most patients, strongly correlated with renal involvement p < 0.001 and was not related to disease severity p = 0.147. CRP, ESR, fibrinogen, d-dimer, albumin and hemoglobin in the peripheral blood showed a strong correlation with the clinical activity of AAV and well identified severe patients. High procalcitonin concentrations correlated with a severe form of the disease, pulmonary involvement with respiratory failure and alveolar hemorrhage (mean 3.41 ng/ml, median 0.91 ng/ml, SD 7.62, p = 0.000), and were associated with the occurrence of infectious complications and the need to administer antibiotic therapy. ANCA antibodies were useful in the evaluation of patients with AAV, the amount of antibodies did not correlate with the severity of vasculitis (p = 0.685) and the results in many patients did not match the expected assumptions.
CONCLUSIONS: CRP, ESR, fibrinogen, d-dimers, albumin and hemoglobin in the peripheral blood correlate well with the activity of vasculitis and identify severe patients. The resolution of microscopic hematuria suggests remission of the disease in the renal area. Procalcitonin may be slightly increased in patients with active AAV without infection, high concentrations are strongly associated with infectious complications. ANCA antibodies should always be interpreted in the context of the observed clinical symptoms.
© 2021. The Author(s).

Entities:  

Keywords:  ANCA; CRP; ESR; complement system; d-dimer; fibrinogen; microhematuria; procalcitonin; vasculitis

Mesh:

Substances:

Year:  2021        PMID: 34445984      PMCID: PMC8390216          DOI: 10.1186/s12882-021-02495-8

Source DB:  PubMed          Journal:  BMC Nephrol        ISSN: 1471-2369            Impact factor:   2.388


  34 in total

1.  Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study.

Authors:  T Girard; A Mahr; L H Noël; J F Cordier; P Lesavre; M H André; L Guillevin
Journal:  Rheumatology (Oxford)       Date:  2001-02       Impact factor: 7.580

2.  Elevated procalcitonin levels in active Wegener's granulomatosis.

Authors:  F Moosig; E Csernok; E Reinhold-Keller; W Schmitt; W L Gross
Journal:  J Rheumatol       Date:  1998-08       Impact factor: 4.666

Review 3.  Thrombosis in vasculitis.

Authors:  Jason Springer; Alexandra Villa-Forte
Journal:  Curr Opin Rheumatol       Date:  2013-01       Impact factor: 5.006

Review 4.  Pathogenesis of ANCA-associated vasculitis.

Authors:  Julia Flint; Matthew D Morgan; Caroline O S Savage
Journal:  Rheum Dis Clin North Am       Date:  2010-06-23       Impact factor: 2.670

5.  Platelet counts as a biomarker in ANCA-associated vasculitis.

Authors:  P Willeke; P Kümpers; B Schlüter; A Limani; H Becker; H Schotte
Journal:  Scand J Rheumatol       Date:  2015-03-06       Impact factor: 3.641

6.  Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection.

Authors:  O K Eberhard; M Haubitz; F M Brunkhorst; V Kliem; K M Koch; R Brunkhorst
Journal:  Arthritis Rheum       Date:  1997-07

7.  A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis.

Authors:  Ravi Suppiah; Chetan Mukhtyar; Oliver Flossmann; Federico Alberici; Bo Baslund; Rajbir Batra; Denise Brown; Julia Holle; Zdenka Hruskova; David R W Jayne; Andrew Judge; Mark A Little; Alessandra Palmisano; Coen Stegeman; Vladimir Tesar; Augusto Vaglio; Kerstin Westman; Raashid Luqmani
Journal:  Rheumatology (Oxford)       Date:  2010-12-13       Impact factor: 7.580

8.  Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study.

Authors:  M M Boomsma; C A Stegeman; M J van der Leij; W Oost; J Hermans; C G Kallenberg; P C Limburg; J W Tervaert
Journal:  Arthritis Rheum       Date:  2000-09

9.  Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis.

Authors:  Javier D Finkielman; Peter A Merkel; Darrell Schroeder; Gary S Hoffman; Robert Spiera; E William St Clair; John C Davis; W Joseph McCune; Andrea K Lears; Steven R Ytterberg; Amber M Hummel; Margaret A Viss; Tobias Peikert; John H Stone; Ulrich Specks
Journal:  Ann Intern Med       Date:  2007-11-06       Impact factor: 25.391

10.  C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Authors:  Jun Yuan; Shen-Ju Gou; Jing Huang; Jian Hao; Min Chen; Ming-Hui Zhao
Journal:  Arthritis Res Ther       Date:  2012-06-12       Impact factor: 5.156

View more
  2 in total

1.  Predicting bacterial infection risk in patients with ANCA-associated vasculitis in southwest China: development of a new nomogram.

Authors:  Naidan Zhang; Jiaxiang Sun; Chaixia Ji; Xiao Bao; Chenliang Yuan
Journal:  Clin Rheumatol       Date:  2022-08-02       Impact factor: 3.650

2.  Late Onset of ANCA Vasculitis as a Side Effect of Levamisole Treatment in Nephrotic Syndrome.

Authors:  Silvia Bernardi; Samantha Innocenti; Marina Charbit; Olivia Boyer
Journal:  Medicina (Kaunas)       Date:  2022-05-11       Impact factor: 2.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.